Emerald Health Pharmaceuticals is focused on treating life-threatening diseases through cannabinoid science. By combining decades of life science and drug development experience with industry-leading expertise in cannabinoid science, EHP is discovering, developing and commercializing proprietary cannabinoid-derived medicines that address significant unmet needs. Currently, EHP is advancing two families of new chemical entities (NCE), derived from cannabidiol (CBD) and cannabigerol (CBG) that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its lead drug candidate, EHP-101, a synthetic derivative of CBD, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, a synthetic derivative of CBG, is focused on treating Huntington’s disease and Parkinson’s disease. The company intends to launch a Phase I clinical study of EHP-101 in 2018.
Cannabinoid interaction with the human endocannabinoid system has been recognized as providing many beneficial clinical and anecdotal health outcomes. Many countries are moving to legalize medical cannabis and estimates suggest that the global cannabis industry may be worth more than USD $146 Billion by 2025. Apart from the broad effects of natural cannabinoids on health, the application of science and biotechnology practices has the potential to significantly alter treatment paradigms broadly speaking and in the realm of neuroscience. Jim DeMesa, MD, will discuss the vital role of the body's endocannabinoid system and use of cannabinoids to address pain, nausea, inflammation, sleep disorders, and neurological diseases through the application of science. In addition, he will discuss avenues to invest in the many opportunities that are emerging with this progressive global cannabis trend.
Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.4 trillion in market capitalisation as of end December 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs.
Torreya Partners LLP is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco